Capital Performance Advisors LLP Akero Therapeutics, Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 20 shares of AKRO stock, worth $646. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20Holding current value
$646% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKRO
# of Institutions
169Shares Held
72.7MCall Options Held
178KPut Options Held
164K-
Janus Henderson Group PLC London, X06.88MShares$222 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$181 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$176 Million2.13% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$169 Million3.88% of portfolio
-
Wellington Management Group LLP Boston, MA5.11MShares$165 Million0.02% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.5B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...